IIPLA News
Tuesday, August 4, 2026

PTAB Final Written Decisions in May 2026 Show 71% Claim Cancellation Rate in IPR and PGR Cases

Analysis of May 2026 PTAB rulings reveals trends in claim survival and amendment outcomes across technology centers

IIPLA News Deskanonymous access0 articles left this week
PTAB Final Written Decisions in May 2026 Show 71% Claim Cancellation Rate in IPR and PGR Cases

In May 2026, the Patent Trial and Appeal Board (PTAB) issued 24 Final Written Decisions in Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings, resulting in the cancellation of 228 instituted claims, representing 71.25% of the total claims reviewed. The decisions include those issued following remand from the Federal Circuit.

Of the 319 instituted claims reviewed in these cases, 91 claims, or 28.44%, survived the PTAB’s scrutiny. This cancellation rate aligns closely with the cumulative average cancellation rate of approximately 74% observed historically in IPR, Covered Business Method (CBM), and PGR Final Written Decisions.

On a per-case basis, the outcomes varied: in 16 decisions (66.67%), all instituted or substitute claims were cancelled; in 4 decisions (16.67%), all claims survived; and in another 4 decisions (16.67%), a mixed outcome was reached where some claims were cancelled while others survived.

Regarding motions to amend, the PTAB has cumulatively granted 703 substitute claims, accounting for 15.6% of proposed amendments, while denying 3,803 substitute claims, or 84.4%, through May 31, 2026. These figures reflect the Board’s rigorous standards for claim amendments in IPR proceedings.

The cumulative survival rate of instituted claims in IPRs, CBMs, and PGRs through May 31, 2026, varies by technology center, although specific breakdowns by technology center were not detailed in the May report.

Similarly, the total number of Final Written Decisions issued through May 31, 2026, is categorized by technology center, providing a framework for analyzing trends within different technical fields.

These statistics offer valuable insights for practitioners and stakeholders in the Business & Consumer Services and Pharmaceuticals & BioTech industries, among others, highlighting the PTAB’s approach to claim validity and amendment requests.

Additional cumulative data and analysis on the PTAB’s IPR, CBM, and PGR decisions are available on the At the PTAB blog, updated through May 31, 2026.

This article serves as a general guide to recent PTAB statistics and does not substitute for specialist legal advice tailored to individual circumstances.

Users are reminded that by accessing the source website, they agree to its use of cookies as outlined in the Privacy Policy.

Share This Article
Ready-to-post copy includes the article link.

PTAB Final Written Decisions in May 2026 Show 71% Claim Cancellation Rate in IPR and PGR Cases In May 2026, the Patent Trial and Appeal Board (PTAB) issued 24 Final Written Decisions in Inter Partes Review (IPR) and Post-Grant Review (PGR) proceedings, cancelling 71.25% of instituted claims. This article examines... Read the full IIPLA article: https://iipla.org/news/ptab-final-written-decisions-in-may-2026-show-71-claim-cancellation-rate-in-ipr-and-pgr-cases

Related Coverage

Continue in the newsroom

Back to newsroom
PatentsGlobal

Paul Weiss Expands Life Sciences Practice with Partner Ian Edvalson in San Francisco

Paul, Weiss, Rifkind, Wharton & Garrison has appointed Ian Edvalson as a partner in its San Francisco office, strengthening the firm’s life sciences transactions and intellectual property practices. Edvalson brings extensive experience advising biopharmaceutical and medical technology companies on licensing, collabora…

Friday, August 7, 2026
PatentsGlobal

Mexican Patent Law Overhaul Demands Early Strategic Planning from Applicants

In the first half of 2026, Mexico implemented sweeping patent reforms that significantly alter how patent applications are prepared, filed, and prosecuted. Key changes include a reduction in the number of substantive office actions and a mandated one-year examination timeline, compelling applicants to adopt earlier an…

Friday, August 7, 2026
PatentsGlobal

China Advances Comprehensive Pharmaceutical IP Protection with New Regulatory Frameworks

China’s pharmaceutical sector is rapidly evolving from generic manufacturing to innovative drug development, supported by a robust intellectual property protection system. Key measures including regulatory data protection, patent term extensions, patent linkage mechanisms, and strengthened judicial and administrative…

Friday, August 7, 2026
PatentsGlobal

T&G Global Posts Strong First-Half Results Driven by Premium Apple Sales

T&G Global reported a 2.6% revenue increase to $572.3 million for the six months ending June 30, 2024, led by a 6.1% rise in its Apples division revenue to $550.9 million. Operating profit grew 30% to $11.6 million before impairment adjustments related to the sale of T&G Fresh businesses. The company highlighted signi…

Friday, August 7, 2026